<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842075</url>
  </required_header>
  <id_info>
    <org_study_id>05-0724(2)</org_study_id>
    <nct_id>NCT00842075</nct_id>
  </id_info>
  <brief_title>Pramlintide in Adolescents With Type 1 Diabetes</brief_title>
  <official_title>Effects of Pramlintide in Adolescents With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that subcutaneous pramlintide as an adjunct to mealtime insulin
      immediately prior to meals can significantly reduce post-prandial glucose concentrations
      compared with mealtime insulin alone in children with type 1 diabetes.

      This is a 36 day, randomized, two-arm, open-label study with a treatment arm (taking
      pramlintide before all meals) and a control arm (diabetes regimen as usual).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants aged 13-17 years who have been diagnosed with type 1 diabetes for more than 1
      year will be invited to participate.Other inclusion factors are:

        -  HbA1c level between 7.5 and 10% inclusive

        -  Currently using carbohydrate to insulin ratio

        -  Acceptable form of birth control

      Exclusion factors:

        -  Oral hyperglycemic agents or medications which might affect blood sugar levels

        -  Recurrent severe hypoglycemia requiring assistance in previous 6 months

        -  Diagnosis of gastroparesis and/or require use of drugs that stimulate gastrointestinal
           motility

        -  Previous use of pramlintide

      The study consists of 2 overnight stays at the CTRC where a continuous glucose monitoring
      system will be worn for twenty-four hours. Blood will be drawn 15 minutes prior to start of
      each meal and for three hours following each meal. Meals will be controlled for carbohydrate,
      fat and protein content. Meals will be identical at each CTRC visit.

      After a baseline visit for all participants, randomization will occur to either Treatment or
      Control.Bolus insulin will be adjusted for participants when beginning pramlintide and will
      likely remain at a reduced rate throughout the trial. All participants will have access to
      staff to assist with insulin dosing. There will be six mandatory phone visits over the 36
      days to ensure the safety of participants in this study.

      Insulin, glucose and glucagon levels will be assessed as well as pramlintide levels at final
      visit of the study. Hypoglycemic events will be tracked, as well as any other adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Value After 28 Days</measure>
    <time_frame>28</time_frame>
    <description>HbA1c values 28 days after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Change After 28 Days Intervention Period</measure>
    <time_frame>28 days</time_frame>
    <description>Mean weight change after 28 days intervention period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1 Symlin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Usual Regimen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual bolus insulin dose at each meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramlintide</intervention_name>
    <description>subcutaneous injection (15 mcg initial dose)prior to meals</description>
    <arm_group_label>1 Symlin</arm_group_label>
    <other_name>Symlin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 13 and 17 years of age, inclusive

          -  Diagnosed with type 1 diabetes for &gt; 1 year

          -  Hemoglobin A1c between 7.5 and 10% inclusive

          -  Currently using carbohydrate to insulin ratio

          -  Acceptable form of birth control

        Exclusion Criteria:

          -  Use of oral hyperglycemic agents or medications affecting blood sugar levels

          -  Recurrent severe hypoglycemia requiring assistance in past 6 months

          -  History of hypoglycemia unawareness

          -  History of gastroparesis requiring use of drugs that stimulate gastrointestinal
             motility

          -  Previous use of pramlintide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Chase, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <results_first_submitted>September 17, 2012</results_first_submitted>
  <results_first_submitted_qc>September 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>adolescents</keyword>
  <keyword>post prandial glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 subjects recruited and completed</recruitment_details>
      <pre_assignment_details>no comments</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Symlin</title>
          <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
        </group>
        <group group_id="P2">
          <title>2 Usual Regimen</title>
          <description>Usual bolus insulin dose at each meal</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Symlin</title>
          <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
        </group>
        <group group_id="B2">
          <title>2 Usual Regimen</title>
          <description>Usual bolus insulin dose at each meal</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">study results do not report this</measurement>
                    <measurement group_id="B2" value="NA">study results do not report this</measurement>
                    <measurement group_id="B3" value="15" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Value After 28 Days</title>
        <description>HbA1c values 28 days after randomization</description>
        <time_frame>28</time_frame>
        <population>pilot study</population>
        <group_list>
          <group group_id="O1">
            <title>1 Symlin</title>
            <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
          </group>
          <group group_id="O2">
            <title>2 Usual Regimen</title>
            <description>Usual bolus insulin dose at each meal</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Value After 28 Days</title>
          <description>HbA1c values 28 days after randomization</description>
          <population>pilot study</population>
          <units>HbA1c %</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" spread="0.71"/>
                    <measurement group_id="O2" value="8.72" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Change After 28 Days Intervention Period</title>
        <description>Mean weight change after 28 days intervention period</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Symlin</title>
            <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
          </group>
          <group group_id="O2">
            <title>2 Usual Regimen</title>
            <description>Usual bolus insulin dose at each meal</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Change After 28 Days Intervention Period</title>
          <description>Mean weight change after 28 days intervention period</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.24"/>
                    <measurement group_id="O2" value="0.04" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Symlin</title>
          <description>Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin</description>
        </group>
        <group group_id="E2">
          <title>2 Usual Regimen</title>
          <description>Usual bolus insulin dose at each meal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. H. Peter Chase</name_or_title>
      <organization>UColorado</organization>
      <phone>303-724-2323</phone>
      <email>peter.chase@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

